Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
- Sponsor
- SCRI Development Innovations, LLC
- Study ID
- NCT00193622
- Phase
- PHASE2
- Status
- Completed
Conditions
- Neoplasms, Unknown Primary
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUG
- Erlotinib — DRUG
Study Details
This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This trial will be one of the first clinical trials to evaluate a combination of targeted agents in the treatment of a solid tumor.
Key Dates
- First listed
- Sep 19, 2005
- Start date
- Apr 30, 2004
- Status verified
- Sep 2010
- Primary completion
- Sep 30, 2005
- Completion
- Jan 31, 2009
Study Design
- Enrollment
- 50 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Overall response rate